Patent intelligence · US
US 11963982
CRISPR/RNA-guided nuclease systems and methods
CRISPR/RNA-guided nuclease systems and methods
Patent details — US 11963982
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 23, 2024
- Expiration
- Apr 18, 2044
- Applicant
- Editas Medicine, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K35/18
Quick answer
US 11963982 (CRISPR/RNA-guided nuclease systems and methods) is held by Editas Medicine, Inc.. Status: granted. Granted Apr 23, 2024. Expires Apr 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Editas Medicine, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K35/18
More from Editas Medicine, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12359223
Systems and methods for modulating chromosomal rearrangements
granted -
US 12331328
CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome
granted -
US 12325854
Crispr-CPF1-related methods, compositions and components for cancer immunotherapy
granted -
US 12201699
Compositions and methods for promoting homology directed repair
granted -
US 12031132
Systems and methods for the treatment of hemoglobinopathies
granted -
US 11952408
HPV-specific binding molecules
granted -
US 11911415
CRISPR/Cas-related methods and compositions for improving transplantation
granted
Frequently asked questions
What is US patent 11963982?
US 11963982 (CRISPR/RNA-guided nuclease systems and methods) is held by Editas Medicine, Inc.. Status: granted. Granted Apr 23, 2024. Expires Apr 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11963982?
Editas Medicine, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does US 11963982 expire?
Our index shows an expiration date of Apr 18, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.